Cell therapies for hematopoietic failure in trauma hemorrhagic shock
DOI:
https://doi.org/10.18203/2320-6012.ijrms20261726Keywords:
Cell therapy, Hematopoietic failure, Traumatic hemorrhagic shockAbstract
Traumatic hemorrhagic shock (T/HS) is clinically associated with hematopoietic failure (HF). HF in T/HS patients is characterized by an increase in the levels of norepinephrine, cytokines, granulocyte-colony stimulating factor and peripheral blood hematopoietic progenitor cells, as well as a decrease in the expression of erythropoietin receptors. Reducing cytokines, vascular dysfunction, tissue damage, apoptosis and HF may be possible with cell-based therapy. Regulatory T cells, mesenchymal stem cells, bone marrow mononuclear cells and induced pluripotent stem cell-derived hematopoietic progenitor cells are all cell-based treatments that have shown promise in improving the prognosis of patients with T/HS by ameliorating bone marrow malfunction or HF. Here, we discuss the latest cell-based therapy approaches for treating HF in T/HS patients.
References
Kumar M, Bhoi S. Impaired hematopoietic progenitor cells in trauma hemorrhagic shock. J Clin Orthop Trauma. J Clin Orthop Trauma. 2016;7 (4):282-5.
Cannon JW. Hemorrhagic shock. N Engl J Med. 2018;378 (4):370-9.
Kauvar DS, Wade CE. The epidemiology and modern management of traumatic hemorrhage: US and international perspectives. Crit Care. 2005;9(5):54.
Griffin GD, Charron D, Al-Daccak R. Autologous white blood cell infusion for trauma, brain trauma, stroke and select immune dysfunction co-morbidities: A promising and timely proposal. Med Hypotheses. 2018;117:7-15.
Livingston DH, Anjaria D, Wu J. Bone marrow failure following severe injury in human. Ann Surg. 2003;238:748–53.
Badami CD, Livingston DH, Sifri ZC. Hematopoietic progenitor cells mobilize to the site of injury after trauma and hemorrhagic shock in rats. J Trauma. 2007;63:596–602.
Millar JK, Kannan KB, Loftus TJ, Alamo IG, Plazas J, Efron PA, et al. Persistent injury-associated anemia: the role of the bone marrow microenvironment. J Surg Res. 2017;15:240-6.
Bible LE, Pasupuleti LV, Gore AV, Sifri ZC, Kannan KB. Chronic restraint stress after injury and shock is associated with persistent anemia despite prolonged elevation in erythropoietin levels. J Trauma Acute Care Surg. 2015;79 (1):91-6.
Cook KM, Sifri ZC, Baranski GM, Mohr AM, Livingston DH. The Role of Plasma G-CSF and Bone Marrow Dysfunction after Severe Trauma. J Am Coll Surg. 2013;216 (1): 57–64.
Kumar M, Bhoi S, Selvi A, Kamal VK, Mohanty S, Rao DN. Evaluation of serum granulocyte colony stimulating factor in patients admitted with trauma hemorrhagic shock. Int J Adv Res Biol Sci. 2015;2(7):107–14.
Kumar M, Bhoi S, Kamal VK, Mohanty S, Rao DN, Galwankar S. Evaluation of bone marrow erythropoietin receptor in trauma hemorrhagic shock. Int J Adv Res Biol Sci. 2015;2(8):43-9.
Vecchio R, Catalano R, Basile F, Spataro C, Caputo M, Intagliata E. Topical hemostasis in laparoscopic surgery. G Chir. 2016;37(6):266-70.
Tien H, Nascimento B Jr, Callum J, Rizoli S. An approach to transfusion and hemorrhage in trauma: current perspectives on restrictive transfusion strategies. Can J Surg. 2007;50(3):202-9.
Mount NM, Ward SJ, Kefalas P, Hyllner J. Cell-based therapy technology classifications and translational challenges. Philos Trans R Soc Lond B Biol Sci. 2015;19:370.
Pati S, Rasmussen TE. Cellular therapies in trauma and critical care medicine: Looking towards the future. PLoS Med. 2017;14(7):1002343.
Kumar M, Rao DN, Mohanty S, Selvi A, Bhoi S. Interleukin (IL)-8 is an early predictor of mortality following trauma hemorrhagic shock. Int J Adv Res Biol Sci. 2015;2(7):12–20.
Kelly LS, Darden DB, Fenner BP, Efron PA, Mohr AM. The hematopoietic stem/progenitor cell response to hemorrhage, injury and sepsis: a review of pathophysiology. Shock. 2021;56(1):30-41.
Schultze JL, Mass E, Schlitzer A. Emerging Principles in Myelopoiesis at Homeostasis and during Infection and Inflammation. Immunity. 2019;50(2):288-301
Kumar M, Rao DN, Bhoi S. Tumour necrosis-α and interleukin-6 suppressed hematopoietic stem cell growth in trauma hemorrhagic shock patients. Shock. 2015;44(2):20.
Nolan JP, Pullinger R. Hypovolaemic shock. BMJ. 2014;348:1139.
Kumar M, Bhoi S, Selvi A, Kamal VK, Mohanty S, Rao DN. Evaluation of circulating Hematopoietic progenitor cells in patients with Trauma Hemorrhagic shock and its correlation with clinical outcome. Int J Crit Illn Inj Sci. 2016;6:56-60.
Huang H, Zhang Q, Liu J, Hao H, Jiang C, Han W. Granulocyte-colony stimulating factor (G-CSF) accelerates wound healing in hemorrhagic shock rats by enhancing angiogenesis and attenuating apoptosis. Med Sci Monit. 2017;23:2644-53.
Kumar A, Choudhary S, Kumar S, Adhikari JS, Kapoor S, Chaudhury NK. Role of melatonin mediated G-CSF induction in hematopoietic system of gamma-irradiated mice. Life Sci. 2022;289:120190.
Baranski GM, Offin MD, Sifri ZC. β-Blockade protection of bone marrow following trauma: the role of G-CSF. J Surg Res. 2011;170:325–31.
Rogiers P, Zhang H, Leeman M, Nagler J, Neels H, Mélot C, et al. Erythropoietin response is blunted in critically ill patients. Intensive Care Med. 1997;23(2):159-62.
Kumar M, Bhoi S. Hematopoietic stem cells: Can it be therapeutic option for the hematopoietic failure in patients with trauma hemorrhagic shock. J. Emerg Med Trauma Shock. 2016;9:51-2.
Li B, Cohen A, Hudson TE, Motlagh D, Amrani DL, Duffield JS. Mobilized human hematopoietic stem/progenitor cells promote kidney repair after ischemia/reperfusion injury. Circulation. 2010;121:2211–20.
Kumar M, Bhoi S. Keshava S. Human-induced pluripotent stem cells derived hematopoietic failure among trauma hemorrhagic shock. Journal of Clinical orthopaedics and Trauma. J Clin Orthop Trauma. 2019;10 (2):269-73. .
Haque R, Lei F, Xiong X, Bian Y, Zhao B, Wu Y, et al. Programming of regulatory T cells from pluripotent stem cells and prevention of autoimmunity. J Immunol. 2012;1;189 (3):1228-36.
Song J. Stem cell-derived regulatory T cells for therapeutic use in arthritis. Autoimmune Infect Dis. 2016;2(3):875.
Haque M, Song J, Fino K, Sandhu P, Song X, Lei F, et al. Stem cell-derived tissue-associated regulatory T cells ameliorate the development of autoimmunity. Sci Rep. 2016;6:20588.
Kumar M, Bhoi S. Mesenchymal stem cell: Can it be used for treatment of trauma hemorrhagic shock. Int J Stud Res. 2015;5(1):15-6.
Kumar M, Bhoi S. Do bone marrow mononuclear cells can be used as a therapeutic target for trauma hemorrhagic shock. Inter J Medical Sci Res Prac. 2015;2(3):1-10.
Griffin GD, Charron D, Al-Daccak R. Autologous white blood cell infusion for trauma, brain trauma, stroke and select immune dysfunction co-morbidities: A promising and timely proposal. Med Hypotheses. 2018;117:7-15.
Valade G, Libert N, Martinaud C, Vicaut E, Banzet S, Peltzer J. Therapeutic potential of mesenchymal stromal cell-derived extracellular vesicles in the prevention of organ injuries induced by traumatic hemorrhagic shock. Front Immunol. 2021;12:749659.
Downloads
Published
How to Cite
Issue
Section
